Home LiteratureArticle Details
PMID: 17476317 Published · ppublish English Journal Article

Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease Neuroimaging Initiative (ADNI).

Alzheimer's & dementia : the journal of the Alzheimer's Association ·Vol. 1 ·No. 1 ·2005-07-00 ·Pages 55-66

Mueller SG, Weiner MW, Thal LJ, Petersen RC, Jack CR, Jagust W, Trojanowski JQ, Toga AW, Beckett L

Abstract

With the increasing life expectancy in developed countries, the incidence of Alzheimer's disease (AD) and thus its socioeconomic impact are growing. Increasing knowledge over the last years about the pathomechanisms involved in AD allow for the development of specific treatment strategies aimed at slowing down or even preventing neuronal death in AD. However, this requires also that (1) AD can be diagnosed with high accuracy, because non-AD dementias would not benefit from an AD-specific treatment; (2) AD can be diagnosed in very early stages when any intervention would be most effective; and (3) treatment efficacy can be reliably and meaningfully monitored. Although there currently is no ideal biomarker that would fulfill all these requirements, there is increasing evidence that a combination of currently existing neuroimaging and cerebrospinal fluid (CSF) and blood biomarkers can provide important complementary information and thus contribute to a more accurate and earlier diagnosis of AD. The Alzheimer's Disease Neuroimaging Initiative (ADNI) is exploring which combinations of these biomarkers are the most powerful for diagnosis of AD and monitoring of treatment effects.

Authors & Affiliations
9 authors, click to expand affiliations / ORCID
Mueller Susanne G
Center for Imaging of Neurodegenerative Diseases, Veterans Administration Medical Center, San Francisco, CA, USA.
Weiner Michael W
Thal Leon J
Petersen Ronald C
Jack Clifford R
Jagust William
Trojanowski John Q
Toga Arthur W
Beckett Laurel
References (113)
113 references, click to expand
  1. Longitudinal magnetic resonance imaging studies of older adults: a shrinking brain.
    J Neurosci. 2003 Apr 15;23(8):3295-301 PMID: 12716936
  2. Looking backward to move forward: early detection of neurodegenerative disorders.
    Science. 2003 Oct 31;302(5646):830-4 PMID: 14593169
  3. Biomarkers of Alzheimer disease in plasma.
    NeuroRx. 2004 Apr;1(2):226-34 PMID: 15717023
  4. Hippocampal volumes in Alzheimer's disease, Parkinson's disease with and without dementia, and in vascular dementia: An MRI study.
    Neurology. 1996 Mar;46(3):678-81 PMID: 8618666
  5. Diffusion and perfusion MR imaging in cases of Alzheimer's disease: correlations with cortical atrophy and lesion load.
    AJNR Am J Neuroradiol. 2001 Jun-Jul;22(6):1030-6 PMID: 11415893
  6. Brain blood flow in the dementias: SPECT with histopathologic correlation in 54 patients.
    Radiology. 1997 Mar;202(3):793-7 PMID: 9051035
  7. Measurement of acetylcholinesterase by positron emission tomography in the brains of healthy controls and patients with Alzheimer's disease.
    Lancet. 1997 Jun 21;349(9068):1805-9 PMID: 9269216
  8. Functional interactions of the entorhinal cortex: an 18F-FDG PET study on normal aging and Alzheimer's disease.
    J Nucl Med. 2004 Mar;45(3):382-92 PMID: 15001677
  9. Altered glucose metabolism in the hippocampal head in memory impairment.
    Neurology. 1998 Jul;51(1):136-42 PMID: 9674792
  10. Cerebral atrophy in Parkinson's disease with and without dementia: a comparison with Alzheimer's disease, dementia with Lewy bodies and controls.
    Brain. 2004 Apr;127(Pt 4):791-800 PMID: 14749292
  11. Differential vulnerability of anterior white matter in nondemented aging with minimal acceleration in dementia of the Alzheimer type: evidence from diffusion tensor imaging.
    Cereb Cortex. 2004 Apr;14(4):410-23 PMID: 15028645
  12. Biochemical markers related to Alzheimer's dementia in serum and cerebrospinal fluid.
    Neurobiol Aging. 2002 Jul-Aug;23(4):485-508 PMID: 12009495
  13. Neocortical and hippocampal glucose hypometabolism following neurotoxic lesions of the entorhinal and perirhinal cortices in the non-human primate as shown by PET. Implications for Alzheimer's disease.
    Brain. 1999 Aug;122 ( Pt 8):1519-31 PMID: 10430835
  14. Reduced medial temporal lobe N-acetylaspartate in cognitively impaired but nondemented patients.
    Neurology. 2005 Jan 25;64(2):282-9 PMID: 15668426
  15. Accurate prediction of histologically confirmed Alzheimer's disease and the differential diagnosis of dementia: the use of NINCDS-ADRDA and DSM-III-R criteria, SPECT, X-ray CT, and Apo E4 in medial temporal lobe dementias. Oxford Project to Investigate Memory and Aging.
    Int Psychogeriatr. 1998 Sep;10(3):271-302 PMID: 9785148
  16. Evaluating the function of hippocampal subregions with high-resolution MRI in Alzheimer's disease and aging.
    Microsc Res Tech. 2000 Oct 1;51(1):101-8 PMID: 11002358
  17. Causative and susceptibility genes for Alzheimer's disease: a review.
    Brain Res Bull. 2003 Jun 30;61(1):1-24 PMID: 12788204
  18. Mild cognitive impairment and Alzheimer disease: regional diffusivity of water.
    Radiology. 2001 Apr;219(1):101-7 PMID: 11274543
  19. Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective.
    Cell. 2005 Feb 25;120(4):545-55 PMID: 15734686
  20. Direct comparison of spatially normalized PET and SPECT scans in Alzheimer's disease.
    J Nucl Med. 2002 Jan;43(1):21-6 PMID: 11801698
  21. Consensus report of the Working Group on: "Molecular and Biochemical Markers of Alzheimer's Disease". The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group.
    Neurobiol Aging. 1998 Mar-Apr;19(2):109-16 PMID: 9558143
  22. Tc-99m ethyl cysteinate dimer SPECT and 2-[F-18]fluoro-2-deoxy-D-glucose PET in Alzheimer's disease. Comparison of perfusion and metabolic patterns.
    Clin Nucl Med. 1999 Aug;24(8):572-5 PMID: 10439176
  23. Temporal lobe atrophy on MRI in Parkinson disease with dementia: a comparison with Alzheimer disease and dementia with Lewy bodies.
    Neurology. 2005 Mar 8;64(5):861-5 PMID: 15753423
  24. Radial width of the temporal horn: a sensitive measure in Alzheimer disease.
    AJNR Am J Neuroradiol. 2002 Jan;23(1):35-47 PMID: 11827874
  25. Patterns of cerebral atrophy in dementia with Lewy bodies using voxel-based morphometry.
    Neuroimage. 2002 Oct;17(2):618-30 PMID: 12377138
  26. Imaging cerebral atrophy: normal ageing to Alzheimer's disease.
    Lancet. 2004 Jan 31;363(9406):392-4 PMID: 15074306
  27. Comparative diagnostic utility of different MR modalities in mild cognitive impairment and Alzheimer's disease.
    Dement Geriatr Cogn Disord. 2002;14(4):198-207 PMID: 12411762
  28. Regional gray and white matter metabolite differences in subjects with AD, with subcortical ischemic vascular dementia, and elderly controls with 1H magnetic resonance spectroscopic imaging.
    Arch Neurol. 1996 Feb;53(2):167-74 PMID: 8639067
  29. Changes in premorbid brain volume predict Alzheimer's disease pathology.
    Neurology. 2003 Aug 26;61(4):487-92 PMID: 12939422
  30. Changes of hippocampal N-acetyl aspartate and volume in Alzheimer's disease. A proton MR spectroscopic imaging and MRI study.
    Neurology. 1997 Dec;49(6):1513-21 PMID: 9409338
  31. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology.
    Neurology. 2001 May 8;56(9):1143-53 PMID: 11342678
  32. Global and local gray matter loss in mild cognitive impairment and Alzheimer's disease.
    Neuroimage. 2004 Oct;23(2):708-16 PMID: 15488420
  33. Comparing gray matter loss profiles between dementia with Lewy bodies and Alzheimer's disease using cortical pattern matching: diagnosis and gender effects.
    Neuroimage. 2004 Sep;23(1):325-35 PMID: 15325380
  34. Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/poitron-emission tomography (FDG/PET).
    Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10966-71 PMID: 11526211
  35. Dynamic susceptibility contrast MRI of regional cerebral blood volume in Alzheimer's disease.
    Am J Psychiatry. 1996 May;153(5):721-4 PMID: 8615424
  36. No epsilon4 gene dose effect on hippocampal atrophy in a large MRI database of healthy elderly subjects.
    Neuroimage. 2005 Feb 15;24(4):1205-13 PMID: 15670698
  37. Structural imaging in the clinical diagnosis of Alzheimer's disease: problems and tools.
    J Neurol Neurosurg Psychiatry. 2001 Jun;70(6):711-8 PMID: 11384998
  38. In vivo visualization of Alzheimer's amyloid plaques by magnetic resonance imaging in transgenic mice without a contrast agent.
    Magn Reson Med. 2004 Dec;52(6):1263-71 PMID: 15562496
  39. Correlation between rates of brain atrophy and cognitive decline in AD.
    Neurology. 1999 May 12;52(8):1687-9 PMID: 10331700
  40. Mapping biochemistry to metabolism: FDG-PET and amyloid burden in Alzheimer's disease.
    Neuroreport. 1999 Sep 29;10(14):2911-7 PMID: 10549796
  41. The MRI pattern of frontal and temporal brain atrophy in fronto-temporal dementia.
    Neurobiol Aging. 2003 Jan-Feb;24(1):95-103 PMID: 12493555
  42. The role of heredity in late-onset Alzheimer disease and vascular dementia. A twin study.
    Arch Gen Psychiatry. 1997 Mar;54(3):264-70 PMID: 9075467
  43. Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia.
    Neurology. 2002 Mar 12;58(5):750-7 PMID: 11889239
  44. 19F and 1H MRI detection of amyloid beta plaques in vivo.
    Nat Neurosci. 2005 Apr;8(4):527-33 PMID: 15768036
  45. Neuroimaging and early diagnosis of Alzheimer disease: a look to the future.
    Radiology. 2003 Feb;226(2):315-36 PMID: 12563122
  46. Frontotemporal dementia and early Alzheimer disease: differentiation with frontal lobe H-1 MR spectroscopy.
    Radiology. 1997 Jun;203(3):829-36 PMID: 9169712
  47. Progressive loss of cortical acetylcholinesterase activity in association with cognitive decline in Alzheimer's disease: a positron emission tomography study.
    Ann Neurol. 2000 Aug;48(2):194-200 PMID: 10939570
  48. Brain 18F-FDG PET in the diagnosis of neurodegenerative dementias: comparison with perfusion SPECT and with clinical evaluations lacking nuclear imaging.
    J Nucl Med. 2004 Apr;45(4):594-607 PMID: 15073255
  49. Ultrastructural hippocampal and white matter alterations in mild cognitive impairment: a diffusion tensor imaging study.
    Dement Geriatr Cogn Disord. 2004;18(1):101-8 PMID: 15087585
  50. Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD.
    Eur J Nucl Med Mol Imaging. 2005 Apr;32(4):486-510 PMID: 15747152
  51. Core biological marker candidates of Alzheimer's disease - perspectives for diagnosis, prediction of outcome and reflection of biological activity.
    J Neural Transm (Vienna). 2004 Mar;111(3):247-72 PMID: 14991453
  52. Hippocampal formation glucose metabolism and volume losses in MCI and AD.
    Neurobiol Aging. 2001 Jul-Aug;22(4):529-39 PMID: 11445252
  53. Treatment of Alzheimer's disease.
    N Engl J Med. 1999 Nov 25;341(22):1670-9 PMID: 10572156
  54. 1H MR spectroscopy in common dementias.
    Neurology. 2004 Oct 26;63(8):1393-8 PMID: 15505154
  55. The search for a rational basis for treatment selection.
    Recent Dev Alcohol. 2003;16:97-113 PMID: 12638633
  56. Patterns of brain activation in people at risk for Alzheimer's disease.
    N Engl J Med. 2000 Aug 17;343(7):450-6 PMID: 10944562
  57. Altered brain activation in cognitively intact individuals at high risk for Alzheimer's disease.
    Neurology. 1999 Oct 22;53(7):1391-6 PMID: 10534240
  58. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease.
    Proc Natl Acad Sci U S A. 2000 May 23;97(11):6037-42 PMID: 10811879
  59. Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease.
    Arch Neurol. 2002 Jun;59(6):972-6 PMID: 12056933
  60. Amyloid-induced neurofibrillary tangle formation in Alzheimer's disease: insight from transgenic mouse and tissue-culture models.
    Int J Dev Neurosci. 2004 Nov;22(7):453-65 PMID: 15465275
  61. Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer's Disease Treatment Studies.
    Am J Psychiatry. 2002 May;159(5):738-45 PMID: 11986126
  62. The current status of Alzheimer's disease genetics: what do we tell the patients?
    Pharmacol Res. 2004 Oct;50(4):385-96 PMID: 15304236
  63. MRI volumetric study of dementia with Lewy bodies: a comparison with AD and vascular dementia.
    Neurology. 2000 Mar 28;54(6):1304-9 PMID: 10746602
  64. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia.
    Proc Natl Acad Sci U S A. 2004 Jan 6;101(1):284-9 PMID: 14688411
  65. Limbic hypometabolism in Alzheimer's disease and mild cognitive impairment.
    Ann Neurol. 2003 Sep;54(3):343-51 PMID: 12953266
  66. Alzheimer's disease-do tauists and baptists finally shake hands?
    Trends Neurosci. 2002 Jan;25(1):22-6 PMID: 11801334
  67. Imaging beta-amyloid plaques and neurofibrillary tangles in the aging human brain.
    Curr Pharm Des. 2004;10(13):1469-92 PMID: 15134570
  68. A comprehensive review of proton magnetic resonance spectroscopy studies in dementia and Parkinson's disease.
    Dement Geriatr Cogn Disord. 2002;14(2):64-76 PMID: 12145453
  69. Progressive cerebral atrophy in MS: a serial study using registered, volumetric MRI.
    Neurology. 2000 Feb 22;54(4):807-12 PMID: 10690967
  70. In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer's disease.
    Neurology. 1999 Mar 10;52(4):691-9 PMID: 10078712
  71. Mild cognitive impairment as a diagnostic entity.
    J Intern Med. 2004 Sep;256(3):183-94 PMID: 15324362
  72. Mapping histology to metabolism: coregistration of stained whole-brain sections to premortem PET in Alzheimer's disease.
    Neuroimage. 1997 Feb;5(2):147-53 PMID: 9345544
  73. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B.
    Ann Neurol. 2004 Mar;55(3):306-19 PMID: 14991808
  74. MRI-derived entorhinal volume is a good predictor of conversion from MCI to AD.
    Neurobiol Aging. 2004 Oct;25(9):1197-203 PMID: 15312965
  75. Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome.
    JAMA. 2001 Nov 7;286(17):2120-7 PMID: 11694153
  76. F2-isoprostanes in Alzheimer and other neurodegenerative diseases.
    Antioxid Redox Signal. 2005 Jan-Feb;7(1-2):269-75 PMID: 15650414
  77. Effect of apolipoprotein E genotype on hippocampal volume loss in aging healthy women.
    Neurology. 2001 Dec 26;57(12):2223-8 PMID: 11756601
  78. Alzheimer disease: quantitative H-1 MR spectroscopic imaging of frontoparietal brain.
    Radiology. 1998 Apr;207(1):91-102 PMID: 9530304
  79. Noninvasive in vivo MRI detection of neuritic plaques associated with iron in APP[V717I] transgenic mice, a model for Alzheimer's disease.
    Magn Reson Med. 2005 Mar;53(3):607-13 PMID: 15723413
  80. Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD.
    Neurology. 2004 Feb 24;62(4):591-600 PMID: 14981176
  81. MRI and CSF studies in the early diagnosis of Alzheimer's disease.
    J Intern Med. 2004 Sep;256(3):205-23 PMID: 15324364
  82. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study.
    Eur J Nucl Med Mol Imaging. 2003 Aug;30(8):1104-13 PMID: 12764551
  83. fMRI evidence of compensatory mechanisms in older adults at genetic risk for Alzheimer disease.
    Neurology. 2005 Feb 8;64(3):501-8 PMID: 15699382
  84. Toxic proteins in neurodegenerative disease.
    Science. 2002 Jun 14;296(5575):1991-5 PMID: 12065827
  85. Effect of donepezil on brain acetylcholinesterase activity in patients with AD measured by PET.
    Neurology. 2001 Feb 13;56(3):408-10 PMID: 11171913
  86. Neuroanatomic substrates of semantic memory impairment in Alzheimer's disease: patterns of functional MRI activation.
    J Int Neuropsychol Soc. 1999 Jul;5(5):377-92 PMID: 10439584
  87. Mild cognitive impairment--beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment.
    J Intern Med. 2004 Sep;256(3):240-6 PMID: 15324367
  88. Alzheimer disease and subcortical ischemic vascular dementia: evaluation by combining MR imaging segmentation and H-1 MR spectroscopic imaging.
    Radiology. 1996 Feb;198(2):537-45 PMID: 8596863
  89. HMPAO SPET and FDG PET in Alzheimer's disease and vascular dementia: comparison of perfusion and metabolic pattern.
    Eur J Nucl Med. 1994 Oct;21(10):1052-60 PMID: 7828614
  90. DWI predicts future progression to Alzheimer disease in amnestic mild cognitive impairment.
    Neurology. 2005 Mar 8;64(5):902-4 PMID: 15753434
  91. Limited donepezil inhibition of acetylcholinesterase measured with positron emission tomography in living Alzheimer cerebral cortex.
    Ann Neurol. 2000 Sep;48(3):391-5 PMID: 10976649
  92. Visualization of beta-amyloid plaques in a transgenic mouse model of Alzheimer's disease using MR microscopy without contrast reagents.
    Magn Reson Med. 2004 Sep;52(3):538-44 PMID: 15334572
  93. Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease.
    Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3334-9 PMID: 11248079
  94. Cortical and subcortical chemical pathology in Alzheimer's disease as assessed by multislice proton magnetic resonance spectroscopic imaging.
    Neurology. 1996 Sep;47(3):696-704 PMID: 8797467
  95. Pattern of cerebral hypoperfusion in Alzheimer disease and mild cognitive impairment measured with arterial spin-labeling MR imaging: initial experience.
    Radiology. 2005 Mar;234(3):851-9 PMID: 15734937
  96. In vivo spectroscopic quantification of the N-acetyl moiety, creatine, and choline from large volumes of brain gray and white matter: effects of normal aging.
    Magn Reson Med. 1999 Feb;41(2):276-84 PMID: 10080274
  97. Methodological considerations for measuring rates of brain atrophy.
    J Magn Reson Imaging. 2003 Jul;18(1):16-24 PMID: 12815635
  98. A comparison of medial and lateral temporal lobe atrophy in dementia with Lewy bodies and Alzheimer's disease: magnetic resonance imaging volumetric study.
    Dement Geriatr Cogn Disord. 2001 May-Jun;12(3):198-205 PMID: 11244213
  99. Functional MR imaging using a visually guided saccade paradigm for comparing activation patterns in patients with probable Alzheimer's disease and in cognitively able elderly volunteers.
    AJNR Am J Neuroradiol. 2000 Mar;21(3):524-31 PMID: 10730646
  100. Molecular targeting of Alzheimer's amyloid plaques for contrast-enhanced magnetic resonance imaging.
    Neurobiol Dis. 2002 Nov;11(2):315-29 PMID: 12505424
  101. Unfolding the role of protein misfolding in neurodegenerative diseases.
    Nat Rev Neurosci. 2003 Jan;4(1):49-60 PMID: 12511861
  102. Different patterns of N-acetylaspartate loss in subcortical ischemic vascular dementia and AD.
    Neurology. 2003 Aug 12;61(3):358-64 PMID: 12913198
  103. Degree of inhibition of cortical acetylcholinesterase activity and cognitive effects by donepezil treatment in Alzheimer's disease.
    J Neurol Neurosurg Psychiatry. 2005 Mar;76(3):315-9 PMID: 15716518
  104. Alzheimer disease therapeutics.
    J Neuropathol Exp Neurol. 2001 Oct;60(10):923-8 PMID: 11589422
  105. Regional N-acetylaspartate reduction in the hippocampus detected with fast proton magnetic resonance spectroscopic imaging in patients with Alzheimer disease.
    Arch Neurol. 2002 May;59(5):828-34 PMID: 12020267
  106. The relationship between fMRI activation and cerebral atrophy: comparison of normal aging and alzheimer disease.
    Neuroimage. 2000 Mar;11(3):179-87 PMID: 10694460
  107. Dynamic susceptibility contrast MR imaging of regional cerebral blood volume in Alzheimer disease: a promising alternative to nuclear medicine.
    AJNR Am J Neuroradiol. 1998 Oct;19(9):1727-32 PMID: 9802497
  108. Pathology and pathways of Alzheimer's disease with an update on new developments in treatment.
    J Am Geriatr Soc. 2003 May;51(5 Suppl Dementia):S314-20 PMID: 12801388
  109. Cognitive correlates of alterations in acetylcholinesterase in Alzheimer's disease.
    Neurosci Lett. 2005 May 20-27;380(1-2):127-32 PMID: 15854764
  110. Coupled reductions in brain oxidative phosphorylation and synaptic function can be quantified and staged in the course of Alzheimer disease.
    Neurotox Res. 2003;5(6):385-98 PMID: 14715441
  111. Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions.
    Neurology. 2005 Mar 8;64(5):834-41 PMID: 15753419
  112. Higher atrophy rate of entorhinal cortex than hippocampus in AD.
    Neurology. 2004 Feb 10;62(3):422-7 PMID: 14872024
  113. 1H-MRS evaluation of metabolism in Alzheimer's disease and vascular dementia.
    Neurol Res. 2004 Jul;26(5):488-95 PMID: 15265265
Article Info
Journal
Alzheimer's & dementia : the journal of the Alzheimer's Association
Abbr.
Alzheimers Dement
ISSN
1552-5279
DOI
10.1016/j.jalz.2005.06.003
Published
2005-07-00
Pages
55-66
Language
English
Region
United States
NLM ID
101231978
PMCID
PMC1864941
Grants
NIA NIH HHS · U01 AG024904-01 · United States
NIA NIH HHS · R01 AG010897-20 · United States
NIA NIH HHS · U01 AG024904 · United States
NIA NIH HHS · U19 AG010483 · United States
NIA NIH HHS · R01 AG010897 · United States
External Links
PubMed source DOI: 10.1016/j.jalz.2005.06.003 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2